CRA consultants supported a pharmaceutical company in its successful challenge of an ANDA filed by a generic manufacturer. The generic company sought to manufacture and sell generic versions of two related diabetes treatments. CRA provided a report analyzing evidence of commercial success for the branded pharmaceutical products as well as deposition and trial testimony.
CRA consultants named top IP professionals in the 2024 IAM Strategy 300
Daniel McGavock, Robert Goldman, and Dr. Richard Razgaitis were recognized as leading IP strategists by Intellectual Asset Management (IAM) in the latest...